Marshall Wace North America’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Marshall Wace North America’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-96,952	Closed	-$4.02M	–	1661
2020 Q3	$4.02M	Buy	+96,952	New	+$4.45M	0.03%	438
2019 Q2	–	Sell	-48,279	Closed	-$5.4M	–	1727
2019 Q1	$5.4M	Buy	48,279 +39,758	+467%	+$4.34M	0.04%	315
2018 Q4	$859K	Sell	8,521 -189,784	-96%	-$19.7M	0.01%	650
2018 Q3	$25.1M	Buy	198,305 +169,606	+591%	+$17.9M	0.17%	130
2018 Q2	$2.41M	Buy	+28,699	New	+$2.1M	0.01%	720
2017 Q3	–	Sell	-53,094	Closed	-$6.42M	–	1566
2017 Q2	$6.42M	Sell	53,094 -62,057	-54%	-$7.19M	0.05%	426
2017 Q1	$13M	Buy	+115,151	New	+$13.4M	0.1%	230

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Marshall Wace North America's ICPT Position: Q4 2020 in Review

Marshall Wace North America sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2020, closing a stake of 96,952 shares — an estimated $4.02M sold.

Marshall Wace North America first reported a position in ICPT in Q1 2017 and held it in 7 quarters. The position peaked at $25.1M in Q3 2018. 175 funds tracked by Wall St. Rank hold ICPT as of Q4 2020.

Marshall Wace North America reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Marshall Wace North America sold 96,952 Intercept Pharmaceuticals, Inc. shares in Q4 2020, an estimated $4.02M.
Marshall Wace North America first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2017 and held it in 7 quarters.
Marshall Wace North America's Intercept Pharmaceuticals, Inc. position peaked at $25.1M in Q3 2018.
175 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.